The Liver Core Center will provide technical and intellectual support and expertise for the liver-related research projects in the Schools of Medicine and Pharmacy of the University of California, San Francisco. It further will provide limited funds for pilot and feasibility studies. The Center will be based on the combined facilities and resources of the Schools of Medicine and Pharmacy, the Moffitt-University Hospital, the San Francisco Veterans Administration Hospital and the San Francisco General Hospital. The overall goals of the Center are to enhance the quality and productivity of individually funded research projects; to foster interdisciplinary communication and collaboration between investigators of different departments and schools; to stimulate new interdisciplinary research projects; to provide technical and procedural resources not available to individual research projects; to optimize the use of available technical and intellectual resources. The main emphasis of the Core Center will be on new and novel concepts and approaches to liver function and structure, both in the physiological state and in a variety of diseases, including drug-induced liver injury. The Core Center will be under the direction of a Program Director, two Deputy Directors, an Executive Committee and an Advisory Board, responsible to the Dean of the School of Medicine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
3P30DK026743-10S1
Application #
3101982
Study Section
Special Emphasis Panel (SRC)
Project Start
1985-07-01
Project End
1990-11-30
Budget Start
1990-07-01
Budget End
1990-11-30
Support Year
10
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Campos-Varela, Isabel; Agudelo, Eliana Z; Sarkar, Monika et al. (2018) Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. Transpl Infect Dis 20:
Dong, Mingjie; Liu, Xianqiong; Evert, Katja et al. (2018) Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death Dis 9:31
Perito, Emily R; Bucuvalas, John; Lai, Jennifer C (2018) Functional status at listing predicts waitlist and posttransplant mortality in pediatric liver transplant candidates. Am J Transplant :
Marco-Rius, Irene; Gordon, Jeremy W; Mattis, Aras N et al. (2018) Diffusion-weighted imaging of hyperpolarized [13 C]urea in mouse liver. J Magn Reson Imaging 47:141-151
Takasaka, Naoki; Seed, Robert I; Cormier, Anthony et al. (2018) Integrin ?v?8-expressing tumor cells evade host immunity by regulating TGF-? activation in immune cells. JCI Insight 3:
von Morze, Cornelius; Tropp, James; Chen, Albert P et al. (2018) Sensitivity enhancement for detection of hyperpolarized 13 C MRI probes with 1 H spin coupling introduced by enzymatic transformation in vivo. Magn Reson Med 80:36-41
Lai, Jennifer C; Segev, Dorry L; McCulloch, Charles E et al. (2018) Physical frailty after liver transplantation. Am J Transplant 18:1986-1994
Kardashian, Ani A; Dodge, Jennifer L; Roberts, John et al. (2018) Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. Liver Int 38:553-563
von Morze, Cornelius (2018) Detecting liver injury non-invasively using hyperpolarized 13 C MRI. Liver Int 38:988-990
Huang, Annsa C; Mehta, Neil; Dodge, Jennifer L et al. (2018) Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 68:449-461

Showing the most recent 10 out of 1119 publications